Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Osteopore To Take Singapore Orthopaedic Sales In-House From 2027

OSX: $0.004 +0.00% · MC: $2M

Osteopore’s subsidiary and DKSH Singapore have agreed to end their exclusive sales and marketing arrangement for Osteopore’s orthopaedic products at the end of 2026, ahead of its scheduled expiry, with Osteopore International set to take over from 2027. The company says direct management is intended to strengthen customer engagement as it expands 3D-printing services and prepares to introduce an injectable bone filler; DKSH’s arrangement began in 2024.

Source announcements: 2026-11-02 09:21 to 2026-11-02 09:21 Sydney time
Story updated 2026-11-02 09:27 Sydney time
SourcesOSX focuses on Ortho line in Singapore via direct selling
Comments